Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 10/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28953974 | 0.86 | PTGS1 (0.67) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL28994215 | 0.84 | BTK (0.53) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL28994232 | 0.82 | BTK (0.62) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL17392022 | 0.82 | DEGS1 (0.62) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL12859107 | 0.82 | ABL1 (0.56) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL30050714 | 0.81 | GRM5 (0.53) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL16594252 | 0.81 | GRM5 (0.53) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL28994195 | 0.81 | GRM5 (0.53) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL26075655 | 0.81 | NPC1 (0.60) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL16604279 | 0.81 | SORT1 (0.60) | ALOX15TSHRCASP1NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| CN-102224143-A | 1h-benzimidazole-5-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INT | 2011-10-19 | — | — | CN | disclosed |
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | ALOX15 3584/4885TSHR 3325/4885CASP1 265/4885 |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | ALOX15 2035/4885TSHR 1013/4885CASP1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.